Breaking News Bar
updated: 8/30/2011 2:08 PM

New cancer pill gives hope, strategy

hello
Success - Article sent! close
  • Pfizer Inc.'s just-approved Xalkori is the first new medicine in several years for deadly lung cancer.

      Pfizer Inc.'s just-approved Xalkori is the first new medicine in several years for deadly lung cancer.
    ASSOCIATED PRESS

 
Associated Press

NEW YORK -- Pfizer Inc.'s just-approved Xalkori, the first new medicine in several years for deadly lung cancer, shows the value of a new research standard: precisely targeting rare diseases linked to gene variants.

That's the view of cancer specialists, Pfizer executives and patients treated with Xalkori. They discussed it shortly after its U.S. approval, along with a companion diagnostic test from Abbott Molecular Oncology, for use in a small subset of lung cancer patients.

Order Reprint Print Article
 
Interested in reusing this article?
Custom reprints are a powerful and strategic way to share your article with customers, employees and prospects.
The YGS Group provides digital and printed reprint services for Daily Herald. Complete the form to the right and a reprint consultant will contact you to discuss how you can reuse this article.
Need more information about reprints? Visit our Reprints Section for more details.

Contact information ( * required )

Success - request sent close

Xalkori is approved for the roughly 4 percent of patients with non-small cell lung cancer who have what's called the ALK fusion gene. That's only about 6,000 Americans a year, but most patients tested had tumors shrink or disappear for months, without the nasty side effects of chemotherapy.

Share this page